HLDF-6 peptide relieves symptoms of abstinence syndrome during experimental opium abuse.
Litvinova
S V
SV
Department of Higher Nervous Activity, Biological Faculty, M. V. Lomonosov Moscow State University.
Kalyuzhnyi
A L
AL
Aristova
V V
VV
Shulgovskii
V V
VV
Kostanyan
I A
IA
Terebelina
N N
NN
Panchenko
L F
LF
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001923:Brain Chemistry; D004195:Disease Models, Animal; D008297:Male; D009021:Morphine Dependence / Q000188:drug therapy*; D009270:Naloxone / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D015260:Neprilysin / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000188:drug therapy*
D009363:Neoplasm Proteins; D011480:Protease Inhibitors; C091149:cell differentiation factor 8.2-kDa; D009270:Naloxone; D015260:Neprilysin